FDA approves Roche's giredestrant for ESR1-mutant breast cancer

The oral SERD slowed tumor progression in the evERA trial, and Roche has said it could become the company's best-selling product.

By Theo Adeyemi, Regulation and biotech correspondent
. 1-minute read.
Two Roche Towers in Basel, Switzerland, photographed in 2022
The Roche Tower buildings in Basel, Switzerland, where Roche is headquartered. Photograph: Michielverbeek/Wikimedia Commons (CC BY-SA 4.0)

The Food and Drug Administration cleared Roche's giredestrant, sold as Wilserdly, on Monday for patients with advanced breast cancer that is HR-positive and HER2-negative and carries an ESR1 mutation, STAT reported. That mutation indicates a tumor is becoming resistant to standard therapies, STAT reported.

Roche has said the drug could become the best-selling product in the company's history, STAT reported. According to STAT, the company viewed the FDA's action as one of the most significant regulatory clearances it had been awaiting. The decision adds to Roche's breast cancer portfolio, where its Genentech subsidiary has a long record with Herceptin even though Roche has fallen behind rivals in oncology in recent years, STAT reported.

In the evERA trial, patients who received giredestrant, an oral medicine from the selective estrogen receptor degrader class, had a longer period before their tumors progressed than those on standard treatment, STAT reported. The approval offers another treatment choice for some patients whose disease has begun to resist hormone-based therapy, STAT reported.

Sources: STAT

Theo AdeyemiRegulation and biotech correspondent

Theo Adeyemi covers drug regulation and the biotech industry for Clinical Observer. He writes from regulators' notices, company filings and published reporting.

Corrections. Report an error to corrections@clinicalobserver.com. Read our corrections policy.